Overview of Vascular Disease
Introduction to vascular pathophysiology, epidemiology, and fundamental principles of vascular surgery
Background
Vascular diseases are a heterogeneous group of conditions involving arteries, veins, and lymphatic vessels. Collectively, they represent one of the leading causes of death and disability worldwide. According to the Global Burden of Disease (GBD) study, ischemic heart disease and stroke remain the top two causes of mortality, while peripheral artery disease (PAD), aneurysmal disease, and venous thromboembolism (VTE) contribute to major morbidity .
The prevalence of vascular diseases is rising with population aging, increased prevalence of diabetes mellitus, hypertension, obesity, and smoking . In high-income countries, improved survival after myocardial infarction and stroke has also resulted in more patients living with chronic vascular conditions. In low- and middle-income countries, the burden is shifting rapidly, often without adequate access to specialized care, necessitating robust regional cardiovascular disease (CVD) prevention and risk assessment strategies .
Epidemiological studies, such as those from Fowkes et al. on PAD , and registries like Swedvasc and Vascunet, demonstrate that vascular disease is not only common but also associated with high long-term mortality and limb loss. Contemporary guidelines from the European Society for Vascular Surgery (ESVS) and Society for Vascular Surgery (SVS), as well as joint statements from the American College of Cardiology (ACC) and American Heart Association (AHA), emphasize integrated management — prevention, early diagnosis, and individualized treatment plans .
Arterial Disease
Atherosclerosis is the predominant etiology of arterial disease. It results from a complex interplay between endothelial dysfunction, lipid deposition, chronic inflammation, and thrombosis. Established risk factors include:
- Modifiable: smoking, hypertension, diabetes, dyslipidemia, obesity, and a sedentary lifestyle.
- Non-modifiable: age, sex, family history, genetic disorders.
Inflammatory mediators (interleukin-6, C-reactive protein) and lipid abnormalities (high low-density lipoprotein [LDL], low high-density lipoprotein [HDL]) play central roles . Management of modifiable risk factors is paramount; for instance, structured exercise programs and the integration of patients with peripheral artery disease (PAD) into cardiac rehabilitation are recommended to address physical inactivity .
Aneurysmal Disease
Abdominal aortic aneurysm (AAA), thoracic aortic aneurysm (TAA), and peripheral aneurysms (popliteal, visceral) develop due to degeneration of vascular wall connective tissue. Smoking is the most consistent modifiable risk factor for AAA, conferring a 5-fold increased risk . Recent epidemiological data highlight the continued global burden of aortic disease, with significant variations in prevalence based on age and sex . Beyond clinical outcomes, there is an increasing recognition of the impact of AAA on patient quality of life, necessitating the integration of patient-reported outcomes (PROs) into clinical assessment to address evolving dynamic patient needs . Familial clustering suggests genetic predisposition, and current guidelines emphasize the importance of genetic screening in patients with thoracic aortic disease, including the transition toward multidisciplinary teams and specialized aortic centers . Systematic reviews supporting society guidelines, including those from the Society for Vascular Surgery (SVS), reinforce the need for specialized management and surveillance in heritable thoracic aortic disease (HTAD) to prevent catastrophic events . Connective tissue disorders such as Marfan, Loeys-Dietz, and Ehlers-Danlos syndromes are strongly associated with TAA and dissection .
> See Also: 4Ch. 4: Aneurysmal Diseases for detailed management of AAA, TAA, and peripheral aneurysms.
Thromboembolic Disease
Virchow's triad — endothelial injury, venous stasis, and hypercoagulability — remains the conceptual framework . Recent evidence suggests that venous stasis may lead to DVT through venous valve hypoxia, which triggers a pro-thrombotic microenvironment even in the absence of overt endothelial denudation .
- Acquired risks: trauma, surgery, malignancy, immobility, oral contraceptives, pregnancy.
- Inherited thrombophilia: Factor V Leiden, prothrombin gene mutation, protein C/S deficiency.
While traditionally viewed as embolic, emerging data in trauma patients suggest that some pulmonary thromboemboli may develop de novo within the pulmonary vasculature, challenging the paradigm that all PE originates from lower extremity DVT .
> See Also: 12Ch. 12: Venous Thromboembolism for comprehensive VTE prevention, diagnosis, and treatment.
Venous Disease
Chronic venous disease (CVD) often follows prior deep vein thrombosis (DVT) with valvular destruction and reflux. Congenital venous malformations and primary valvular incompetence also contribute. Venous hypertension leads to edema, pigmentation, lipodermatosclerosis, and ulceration .
| Category | Risk Factors |
|---|---|
| Modifiable | Smoking, Hypertension, Diabetes, Dyslipidemia, Obesity, Inactivity |
| Non-modifiable | Age, Male sex, Family history, Connective tissue disorders |
- **Risk Factors**
- Smoking, Hypertension, Diabetes, Dyslipidemia, Obesity, Inactivity
- **Risk Factors**
- Age, Male sex, Family history, Connective tissue disorders
Use CEAP for standardized reporting (C1–C6 with etiologic, anatomic, pathophysiologic domains) and VCSS for severity. Post-thrombotic syndrome and primary valvular reflux share a final common pathway of venous hypertension leading to skin changes and ulceration .
> See Also: 13Ch. 13: Chronic Venous Insufficiency for detailed venous disease management including CEAP classification applications.
Atherosclerosis
Endothelial dysfunction allows low-density lipoprotein (LDL) to penetrate the intima, where it undergoes oxidation. Monocytes adhere, migrate, and differentiate into macrophages, forming foam cells. Smooth muscle proliferation and extracellular matrix deposition lead to fibrous cap formation. Plaque rupture triggers platelet activation and thrombus formation, which can result in acute ischemic events . Given the central role of LDL in this process, lipid-lowering therapy is foundational to management, although real-world adherence to statin therapy remains a significant clinical challenge influenced by various patient and provider determinants .
Aneurysm Formation
Aneurysmal disease is mediated by proteolytic degradation of elastin and collagen in the aortic wall, upregulation of matrix metalloproteinases, chronic inflammation, and biomechanical stress. Abdominal aortic aneurysm (AAA) is associated with infiltration of T cells and macrophages, while TAA often relates to genetic mutations affecting connective tissue proteins such as fibrillin .
Thrombosis
Arterial thrombosis is platelet-driven, while venous thrombosis is fibrin-rich. Both involve the coagulation cascade and interplay between clotting factors and endothelium. Atrial fibrillation (AF) is a major source of systemic arterial thromboembolism, where stasis, particularly in the left atrial appendage, leads to thrombus formation . Pulmonary embolism (PE) arises from embolization of venous thrombi .
Venous Insufficiency
Venous reflux increases hydrostatic pressure, leading to capillary leak, leukocyte trapping, inflammation, and tissue damage. This cascade underlies chronic venous ulcers . Management of chronic venous insufficiency (CVI) and associated lymphedema often involves compression therapy; non-pneumatic compression (NPC) has been recognized for its clinical utility in managing these conditions . For refractory venous ulcers, platelet-rich plasma (PRP) has shown clinical efficacy in improving healing rates and outcomes .
Diagnostics and Imaging
Diagnosis integrates history, physical examination, hemodynamic testing, and imaging.
Clinical Assessment
History of claudication, rest pain, ulceration, or embolic events is essential. On examination:
- Arterial: pulse deficit, bruits, trophic skin changes. In patients with diabetes, a comprehensive foot examination is mandatory to identify neuropathy, deformity, and skin integrity issues .
- Venous: varicosities, edema, skin pigmentation, ulceration.
- Lymphatic: swelling, non-pitting edema, skin thickening.
For peripheral artery disease (PAD), risk-stratify limb threat with Wound, Ischemia, and foot Infection (WIfI) staging and integrate with patient risk, limb threat, and anatomic pattern (PLAN) to guide revascularization strategy . Angiographic scoring systems within the PLAN framework are increasingly utilized to predict clinical outcomes and technical success .
Perioperative Cardiac Risk Assessment
Vascular surgery patients have high rates of coronary artery disease. The Revised Cardiac Risk Index (RCRI) helps stratify perioperative major adverse cardiac events (MACE) risk before non-cardiac surgery . Vascular procedures (especially aortic and lower extremity) are classified as high-risk surgery, contributing 1 point to the RCRI score. In patients with established atherosclerotic cardiovascular disease (ASCVD), the SMART2-HF model may be used to predict the risk of incident heart failure, further refining the clinical profile of the high-risk vascular patient .
Hemodynamic Testing
- ankle-brachial index (ABI): Sensitivity ~80%, specificity ~95% for peripheral arterial disease (PAD) . Limitations: falsely elevated in calcified arteries.
- toe-brachial index (TBI): Preferred over ABI in patients with diabetes or chronic kidney disease (CKD) due to medial arterial calcification and non-compressible vessels .
- transcutaneous oxygen tension (TcPO₂): Values <30 mmHg indicate severe ischemia with poor wound-healing potential; 30–39 mmHg suggests moderate ischemia; ≥40 mmHg indicates adequate perfusion .
- Segmental pressures and plethysmography: Localize stenoses and assess venous reflux.
In chronic limb-threatening ischemia (CLTI), toe pressure <30 mmHg or TcPO₂ <30 mmHg indicates severe ischemia and poor wound-healing potential. The Wound, Ischemia, and foot Infection (WIfI) staging system integrates hemodynamics (toe pressure, TcPO₂), wound characteristics, and infection severity to stratify limb threat and guide revascularization decisions . See 10Ch. 10 for complete WIfI classification.
Imaging Modalities
- Duplex Ultrasound (DUS): First-line for peripheral arterial disease (PAD), abdominal aortic aneurysm (AAA), carotid stenosis, venous reflux, and deep vein thrombosis (DVT). Operator-dependent but safe and inexpensive . In patients with diabetes, DUS is the preferred initial imaging modality for PAD .
- computed tomography angiography (CTA): Provides high-resolution 3D reconstructions for aneurysms and PAD; requires contrast and radiation . CTA is highly effective for identifying the multi-segmental and infrapopliteal disease patterns common in diabetic patients .
- magnetic resonance angiography (MRA): Useful when CTA contraindicated; gadolinium-based contrast or time-of-flight techniques . MRA is an alternative for detailed anatomical assessment in PAD, particularly when avoiding ionizing radiation is prioritized .
- Catheter angiography: Remains the gold standard; allows simultaneous diagnosis and treatment but carries procedural risk .
- intravascular ultrasound (IVUS) and optical coherence tomography (OCT): Provide intraluminal detail; OCT superior for plaque characterization, IVUS for stent sizing .
- positron emission tomography/computed tomography (PET/CT): Detects active inflammation in aneurysm walls and vulnerable plaques .
Medical Management
- Lifestyle modification: Smoking cessation reduces abdominal aortic aneurysm (AAA) expansion and peripheral arterial disease (PAD) progression . Exercise therapy improves walking distance in PAD. Comprehensive risk factor modification, including diet and physical activity, remains the cornerstone of cardiovascular prevention .
- Antiplatelet therapy: Aspirin or clopidogrel for secondary prevention in symptomatic atherosclerotic disease .
- Anticoagulation: Low-dose rivaroxaban plus aspirin benefits select PAD patients; see 10Ch. 10 for COMPASS/VOYAGER-PAD evidence and patient selection criteria.
- Lipid lowering: High-intensity statins reduce events and slow aneurysm growth . Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors provide additional risk reduction in statin-intolerant or high-risk patients .
- Blood pressure and glycemic control: Angiotensin-converting enzyme (ACE) inhibitors and tight glycemic control improve vascular outcomes . In patients with diabetes and PAD, management requires intensive risk factor control and the use of evidence-based glucose-lowering therapies to reduce the risk of major adverse limb and cardiovascular events .
- Risk stratification: In patients with established atherosclerotic cardiovascular disease (ASCVD), the SMART2-HF model can be utilized to predict the risk of incident heart failure, facilitating early intervention and personalized management .
Open Surgery
- Bypass grafting: Autologous vein remains gold standard for infrainguinal bypass . See 10Ch. 10 for BEST-critical limb ischemia (CLI)/BASIL evidence.
- carotid endarterectomy (CEA): Standard for symptomatic carotid stenosis >50% and select asymptomatic stenosis >70%. See 7Ch. 7 for NASCET, CREST, and patient selection.
- Open abdominal aortic aneurysm (AAA) repair: Durable long-term results, particularly for young/fit patients . See 4Ch. 4.
- Thrombectomy/Embolectomy: Fogarty embolectomy remains the de facto gold standard for surgical extraction of acute embolic occlusion .
> See Also: Disease-specific surgical details: 4Ch. 4, 7Ch. 7, 10Ch. 10.
Endovascular Therapy
- percutaneous transluminal angioplasty (PTA): Widely used for focal lesions, especially in iliac arteries.
- Drug-coated devices: Drug-coated balloons (DCB) and drug-eluting stents (DES) improve patency in femoropopliteal disease; see 10Ch. 10 for evidence and paclitaxel safety considerations.
- endovascular aneurysm repair (EVAR)/thoracic endovascular aortic repair (TEVAR): Reduced perioperative mortality compared to open repair; see 4Ch. 4 for RCT evidence and patient selection.
- Thrombectomy: Penumbra Indigo and AngioJet systems effective in acute limb ischemia (ALI) .
- Embolization: Indicated for visceral aneurysms, endoleaks, and hemorrhage control, including arterial embolization for hemodynamically unstable pelvic fractures .
- resuscitative endovascular balloon occlusion of the aorta (REBOA): Utilized for temporary hemorrhage control in trauma patients with life-threatening subdiaphragmatic bleeding, often as part of a multi-modal approach alongside angioembolization or surgery .
> See Also: Disease-specific techniques: 4Ch. 4, 10Ch. 10, 16Ch. 16.
Hybrid Approaches
Hybrid approaches combine open and endovascular methods, such as iliac stenting with femoral thromboendarterectomy (TEA) or visceral debranching with thoracic endovascular aortic repair (TEVAR), offering flexibility for complex anatomy . These strategies are increasingly utilized in the management of acute and chronic mesenteric ischemia, particularly for complex lesions requiring combined access . Furthermore, long-term registry data support hybrid repair as a durable treatment modality for extracranial carotid artery aneurysms (ECAA) .
Open
Endovascular
Hybrid
- Durable outcomes
- proven long-term survival
- Higher perioperative risk
- longer recovery
- Minimally invasive
- lower perioperative risk
- Requires surveillance
- higher reintervention rates
- Tailored to complex cases
- Technically demanding
- resource-intensive
Open
- Durable outcomes
- proven long-term survival
- Higher perioperative risk
- longer recovery
Endovascular
- Minimally invasive
- lower perioperative risk
- Requires surveillance
- higher reintervention rates
Hybrid
- Tailored to complex cases
- Technically demanding
- resource-intensive
Follow-up
Surveillance ensures early detection of complications such as graft stenosis, endoleaks, and restenosis.
- endovascular aneurysm repair (EVAR): computed tomography angiography (CTA) or duplex ultrasound (DUS) at 1 month, 12 months, then annually (European Society for Vascular Surgery (ESVS), Society for Vascular Surgery (SVS)) .
- Open abdominal aortic aneurysm (AAA) repair: Imaging only if symptomatic.
- Bypass grafting: DUS at 1–3, 6, 12 months, then annually .
- Carotid (carotid endarterectomy (CEA)/carotid artery stenting (CAS)): DUS at 6 months, then every 1–2 years .
- Venous intervention: DUS at 1–3 months, then as clinically indicated.
For EVAR, risk-stratified surveillance per ESVS AAA guidance suggests that many standard EVARs may transition to duplex-based annual follow-up after a stable first-year scan, while complex anatomies or endoleaks require individualized schedules . Recent multicenter data supports the implementation of these updated algorithms, highlighting that 1-year sac dynamics (specifically sac shrinkage) are critical for predicting long-term stability and further refining the intensity of follow-up .
Surveillance Intervals
- endovascular aneurysm repair (EVAR)
- **1–3 mo**
- ✔
- **12 mo**
- ✔
- **Annual**
- ✔
- Open abdominal aortic aneurysm (AAA)
- **Annual**
- Symptom-driven
- Bypass graft
- **1–3 mo**
- ✔
- **6 mo**
- ✔
- **12 mo**
- ✔
- **Annual**
- ✔
- Carotid (carotid endarterectomy (CEA)/carotid artery stenting (CAS))
- **1–3 mo**
- ✔
- **6 mo**
- ✔
- **12 mo**
- ✔
- **Annual**
- ✔
- Venous interventions
- **1–3 mo**
- ✔
- **Annual**
- As indicated
Carotid surveillance per 7Ch. 7: DUS at 1, 6, and 12 months, then annually; adjust based on residual stenosis, periprocedural complications, or contralateral disease .
Foundational vascular anatomy and hemodynamics
The vascular system is organized into distinct anatomic territories, each with characteristic arterial, venous, and lymphatic components. Arterial anatomy includes the cervical and cerebrovascular territories, the thoracic aorta with its arch zones (0–3), the visceral and mesenteric circulation, the iliofemoral system, and the below-knee angiosomes. Key collateral networks include the circle of Willis for cerebral perfusion, the marginal artery of Drummond and arc of Riolan for mesenteric collateralization, and the genicular network around the knee.
Venous anatomy comprises the deep, superficial, and perforator systems, with the calf-muscle pump playing a central role in venous return. The lymphatic channels parallel the vascular tree and drain into regional lymph nodes.
Angiosome-directed revascularization refers to restoring blood flow to specific tissue zones based on direct arterial supply. In chronic limb-threatening ischemia (CLTI), this approach may improve wound healing outcomes, though evidence remains evolving . Standard vascular nomenclature includes aortic arch zones (0–3), femoropopliteal segments, and named tibial vessels (anterior tibial, posterior tibial, and peroneal arteries).
References
- 1.Benjamin EJ, et al. Heart disease and stroke statistics. *Circulation*. 2019. PubMed. US burden data.PubMed-indexed article2019
March 5, 2019 e1 WRITING GROUP MEMBERS Emelia J. Virani, MD, PhD, FAHA, Chair Elect On behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee.
- 2.Criqui MH, Aboyans V. Epidemiology of PAD. *Circ Res*. 2015. PubMed. PAD review.PubMed-indexed article2015
An updated, integrated overview of the epidemiology of PAD is provided, a focused literature review was conducted, and several newer risk markers have shown independent associations with PAD.
- 3.ESVS. Editor's Choice -- European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Abdominal Aorto-Iliac Artery Aneurysms. Eur J Vasc Endovasc Surg. 2024. PMID: 38307694. DOI: 10.1016/j.ejvs.2023.11.002.PubMed-indexed articleClinical practice guideline2024
- 4.Fowkes FGR, et al. Global prevalence of PAD. *Lancet*. 2013. PubMed. Prevalence study.PubMed-indexed article2013
This study provides the first comparison of the prevalence of peripheral artery disease between high-income countries (HIC) and low-income or middle- income countries (LMIC), establishes the primary risk factors for peripheral artery diseases in these settings, and estimates the number of people living with peripheral artery Disease regionally and globally.
- 5.GBD 2019 Vascular Disease Collaborators. Global burden of vascular disease. *Lancet*. 2020. PubMed. Global epidemiology.PubMed-indexed article2020
Georgia has a high NCD burden and results from the survey showed an increase in obesity and elevated blood pressure since 2010, and comprehensive public health interventions are needed to control the heath security threats of major NCDs and their risk factors in the future.
- 6.
- 7.Chaikof EL, et al. SVS Clinical Practice Guidelines on aortic disease. *J Vasc Surg*. 2018;67:2–77. PubMed. Aortic guideline.PubMed-indexed article2018
A door‐to‐intervention time of <90 minutes is suggested, based on a framework of 30‐30‐30 minutes, for the management of the patient with a ruptured aneurysm, and the Vascular Quality Initiative mortality risk score is suggested for mutual decision‐making with patients considering aneurYSm repair.
- 8.
- 9.
- 10.Libby P. Atherosclerosis mechanisms. *Nature*. 2021. PubMed. Review.PubMed-indexed article2021
Advances in understanding of the biology of atherosclerosis have opened avenues to therapeutic interventions that promise to improve the prevention and treatment of now-ubiquitous atherosclerotic diseases.
- 11.Isselbacher EM et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2022. PMID: 36322642.PubMed-indexed articleClinical practice guideline2022
- 12.
- 13.
- 14.
- 15.Martin SS et al. 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation. 2025. PMID: 39866113.PubMed-indexed article2025
The Statistical Update represents a critical resource for the lay public, policymakers, media professionals, clinicians, health care administrators, researchers, health advocates, and others seeking the best available data on these factors and conditions.
- 16.Rutherford RB (ed.). *Rutherford’s Vascular Surgery and Endovascular Therapy*. 9th Ed. Elsevier, 2018. Textbook reference.Textbook referenceTextbook2018
- 17.Sakalihasan N, Michel JB, et al. AAA pathogenesis. *Nat Rev Cardiol*. 2018. PubMed. AAA biology.PubMed-indexed article2018
Elective repair of AAA with open surgery or endovascular aortic repair (EVAR) should be considered to prevent AAA rupture, although the morbidity and mortality associated with both techniques remain non-negligible.
- 18.
- 19.
- 20.Rutherford RB (ed.). *Rutherford’s Vascular Surgery and Endovascular Therapy.* 9th Ed. Philadelphia: Elsevier; 2018. Authoritative textbook.Textbook referenceTextbook2018
- 21.
- 22.Eklöf B, Rutherford RB, Bergan JJ, et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg. 2004;40(6):1248–1252.PubMed-indexed article2004
The CEAP classification for chronic venous disorders was developed in 1994 by an international ad hoc committee of the American Venous Forum, endorsed by the Society for Vascular Surgery, and incorporated into "Reporting Standards in Venous Disease" in 1995.
- 23.Greenhalgh RM, et al. EVAR-1. *NEJM*. 2010. PubMed. EVAR trial.PubMed-indexed article2010
In this large, randomized trial, endovascular repair of abdominal aortic aneurysm was associated with a significantly lower operative mortality than open surgical repair and was associated with increased rates of graft-related complications and reinterventions and was more costly.
- 24.Kahn SR, et al. Post-thrombotic syndrome. *Blood*. 2014;123:3972–80. PubMed. Venous sequelae.PubMed-indexed article2014
This scientific statement is to provide an up-to-date overview of the postthrombotic syndrome (PTS), a frequent, chronic complication of deep venous thrombosis (DVT), and to provide practical recommendations for its optimal prevention, diagnosis, and management.
- 25.
- 26.Writing Committee Members. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. J Thorac Cardiovasc Surg. 2023. PMID: 37389507.PubMed-indexed articleClinical practice guideline2023
- 27.Jacobowitz GR et al. Non-pneumatic compression and its clinical utility in management of lymphedema. A position statement endorsed by the American Venous Forum and the American Venous and Lymphatic Society. J Vasc Surg Venous Lymphat Disord. 2025. PMID: 41271100.PubMed-indexed articleClinical practice guideline2025
- 28.
- 29.ACC/AHA. Management of Lower Extremity Peripheral Artery Disease: Guidelines From the ACC/AHA. 2026. PMID: 41252847.PubMed-indexed articleClinical practice guideline2026
- 30.Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg. 2019;69(6S):3S-125S.e40.PubMed-indexed article2019
The GVG proposes a new Global Anatomic Staging System (GLASS), which involves defining a preferred target artery path (TAP) and then estimating limb-based patency (LBP) resulting in three stages of complexity for intervention.
- 31.Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. *Circulation*. 1999;100:1043–1049.PubMed-indexed article1999
In stable patients undergoing nonurgent major noncardiac surgery, this index can identify patients at higher risk for complications and may be useful for identification of candidates for further risk stratification with noninvasive technologies or other management strategies.
- 32.
- 33.
- 34.
- 35.Potier L, et al. Toe pressure and toe–brachial index for PAD in diabetes. *Diabetes Care*. 2011;34:134–9. PubMed. TBI utility.PubMed-indexed article2011
The ABI could be used in patients with diabetes, but values should be interpreted with precision, according to the clinical situation, when there is concomitant clinical peripheral neuropathy or high risk of arterial calcification.
- 36.Schepers A, et al. Predictive value of TcPO₂ in CLTI. *Eur J Vasc Endovasc Surg*. 2010;40:647–52. PubMed. TcPO₂ evidence.PubMed-indexed article2010
In the long term, inframalleolar bypass is a satisfactory option for limb salvage and female sex was associated with worse results for cumulative patency and limb salvage.
- 37.
- 38.Ali ZA, et al. Optical coherence tomography and IVUS in vascular disease. *JACC Intv*. 2016;9:2142–56. PubMed. Intravascular imaging.PubMed-indexed article2016
This randomised controlled trial sought to establish whether or not a novel OCT-based stent sizing strategy would result in a minimum stent area similar to or better than that achieved with IVUS guidance and better than those achieved with angiography guidance alone.
- 39.Figueroa AL, et al. PET imaging of vascular inflammation. *JACC*. 2015;65: 2113–26. PubMed. PET applications.PubMed-indexed article2015
An 18-year-old girl with short stature presented with a history of fever, dyspnea, and cyanosis and had clubbing, hypertelorism, prominent epicanthus, bilateral anotia.
- 40.Moneta GL, et al. Duplex ultrasound criteria for PAD. *J Vasc Surg*. 2010;52: 539–48. PubMed. DUS accuracy.PubMed-indexed article2010
In patients with severe upper extremity ischemia not amenable to standard revascularization techniques, AVR should be considered to provide limb salvage and maximize hand function.
- 41.Prince MR, et al. MR angiography: principles and clinical applications. *Radiology*. 2016;281:630–48. PubMed. MRA overview.PubMed-indexed article2016
99mTc-labeled PSMA inhibitor MIP-1404 is a promising SPECT tracer for detection of locally recurrent or metastatic prostate cancer.
- 42.Sun Z. CT angiography of AAA. *Biomed Imaging Interv J*. 2011;7:e2. PubMed. CTA review.PubMed-indexed article2011
Patients can benefit from multislice CT angiography that provides a rapid and accurate diagnosis while avoiding unnecessary invasive coronary Angiography procedures, with a focus on the diagnostic accuracy of coronary artery disease.
- 43.White CJ. Catheter-based angiography. *Circulation*. 2006;113:1460–8. PubMed. Diagnostic gold standard.PubMed-indexed article2006
Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic) A Collaborative Report from the American Association for Vascular Surgery/Society for V vascular surgery,* Society for Cardiovascular Angiography and Interventions, Society forVascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines.
- 44.Golledge J, et al. Medical therapies to limit AAA growth. *Lancet Diabetes Endocrinol*. 2017;5:185–93. PubMed. AAA medical management.PubMed-indexed article2017
Continuous efforts to develop a medical therapy to limit abdominal aortic aneurysm growth are described, with no benefit reported of the antibiotic doxycycline, a mast cell inhibitor, an angiotensin‐converting enzyme inhibitor, or a calcium channel blocker in limiting AAA growth.
- 45.CAPRIE Steering Committee. Clopidogrel vs aspirin in atherothrombosis. *Lancet*. 1996;348:1329–39. PubMed. Antiplatelet RCT.PubMed-indexed article1996
TAK-029 may be effective in patients suffering from arterial thrombosis diseases, which are refractory to these conventional antithrombotic agents, and in humans, guinea pigs and monkeys.
- 46.Sabatine MS, et al. PCSK9 inhibition (FOURIER). *NEJM*. 2017;376:1713–22. PubMed. Lipid lowering.PubMed-indexed article2017
Evolocumab significantly reduced cardiovascular outcomes consistently in patients with and without diabetes at baseline and did not increase the risk of new-onset diabetes in patients without diabetes in FOURIER.
- 47.AHA. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024. PMID: 38743805. DOI: 10.1161/CIR.0000000000001251.PubMed-indexed articleClinical practice guideline2024
- 48.Conte MS. Bypass outcomes in contemporary practice. *Circulation*. 2018;138:1435–48. PubMed. Bypass durability.PubMed-indexed article2018
In this prospective, randomized, placebo-controlled clinical trial, ex vivo treatment of lower extremity vein grafts with edifoligide did not confer protection from reintervention for graft failure, and there was no significant difference between the treatment groups in the primary or secondary trial end points, primary graft patency, or limb salvage.
- 49.
- 50.Rutherford's Vascular Surgery and Endovascular Therapy. 10th ed. 2022. Ch. 104, Acute Limb Ischemia: Surgical and Endovascular Treatment, p. 1698TextbookTextbook referenceTextbook2022
Rutherford's Vascular Surgery and Endovascular Therapy. 10th ed.. 2022. Ch. 104, Acute Limb Ischemia: Surgical and Endovascular Treatment, p. 1698
Textbook reference - 51.
- 52.Hsiao HM, et al. Mechanical thrombectomy in ALI. *J Vasc Surg*. 2019;69:1127–36. PubMed. Device outcomes.PubMed-indexed article2019
BVF performed after VIV TAVR results in improved residual gradients, associated with challenges in achieving optimum THV position and expansion, and could be considered in selected clinical cases.
- 53.
- 54.Bisdas T, et al. Hybrid revascularization strategies. *J Vasc Surg*. 2013;57:116–23. PubMed. Hybrid therapy.PubMed-indexed article2013
complex and simple hybrid procedures enable multilevel revascularizations in high-risk patients with comparable patency and limb salvage and Limb salvage in patients who presented with critical limb ischemia was better in the cHYBRID group than other groups.
- 55.
- 56.Aburahma AF, Campbell JE, Mousa AY, et al. Clinical Practice Guidelines for Follow-up of Patients after Endovascular Aneurysm Repair. J Vasc Surg. 2019;70(1):335–342.PubMed-indexed article2019
It is reasonable to consider the implementation of ERAS pathways in the care of vascular surgery patients, specifically those undergoing open aortic operations, but many of the details will be based on limited data and extrapolation from other surgical specialties until further research is done.
- 57.Almasri J, et al. Surveillance of bypass grafts. *BMJ*. 2018;360:k941. PubMed. Surveillance evidence.PubMed-indexed article2018
Patency rates are highest for saphenous vein bypass, whereas both patency and limb salvage are markedly inferior for prosthetic grafting to below the knee targets, particularly for severe anatomic patterns of disease treated via endovascular means.
- 58.Esposito D, et al. Implementation of the Updated European Society for Vascular and Endovascular Surgery Proposed Endovascular Aneurysm Repair Surveillance Algorithm in a Multicentre Cohort with a Minimum Five Year Follow Up Adherence: Further Improvement of Results via 1 Year Sac Dynamics. Eur J Vasc Endovasc Surg. 2025. PMID: 40216188.PubMed-indexed articleRegistry / cohort2025
- 59.
- 60.ESVS. Review of the European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Abdominal Aorto-Iliac Artery Aneurysms: what is new and prospects for development. 2024. PMID: 41801947. DOI: 10.33029/1027-6661-2024-30-2-131-136.PubMed-indexed articleClinical practice guideline2024
Educational use only
AI assists this editorial workflow. Published updates are human-reviewed before publication.
Not intended to diagnose, monitor, predict, prognose, treat, or alleviate disease.
Verify clinically relevant information against primary sources and current guidelines.